Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
12/2009
12/02/2009CN100563455C A Chinese medicine compound health tea
12/01/2009US7625948 Ester that inhibits MTP in intestines as antilipemic agents for side effect reduction
12/01/2009US7625937 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators
12/01/2009US7625929 Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics
12/01/2009US7625925 Pyrazolo[1,5-a]pyridines and medicines containing the same
12/01/2009US7625919 Osteoporosis; oral diseases; bone disorders; atherosclerosis; antiarthritic agents; autoimmune disease; cachexia
12/01/2009US7625916 Medicinal composition
12/01/2009US7625914 2(S)-Ethoxy-3-{4-[2-(3-heptyl-1-methylureido)thiazol-4-yl]phenyl}propanoic acid; dermatology, and cardiovascular diseases, immune diseases, lipid metabolism diseases; veterinary medicine
12/01/2009US7625913 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease
12/01/2009US7625909 N-{3-[2-(2-Fluoro-4-methoxyphenyl)-ethyl]-4-oxo-3,4-dihydroquinazolin-7yl}-N-indan-2-yl-3,5-dimethylpiperazine-1-carboxamidine; melanocortin-4 receptor agonists; diabetes
12/01/2009US7625906 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
12/01/2009US7625888 {(1R)-1-(2,4,5-Trifluorobenzyl)-2-[9-(trifluoromethyl)-5,6-dihydrobis[1,2,4]triazolo[1,5-a:3',4'-c]pyrazin-3-yl]ethyl}amine, hydrochloride; metformin; treating non-insulin dependent (Type 2) diabetes in a mammal
12/01/2009US7625887 e.g. 2-[3,5-trans-5-(3-aminophenyl)-7-chloro-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-N-(2-fluorobenzyl)acetamide; G-protein-coupled receptor (TGR5) agonist; central nervous system diseases; antiinflammatory agent; learning enhancement; angina pectoris, arrhythmia, bronchial asthma
12/01/2009US7625883 Choline Salt of L- alpha -glycero-phospho-D-mio-inositol; alpha -glycero-phospho-D-mio-inositol tetrabutylammonium salt; treatment of pathologies mediated by the activation or over stimulation of cytololilc phospholipase-2 (PLA2), particularly, septic shock and viral and bacterial infections
12/01/2009CA2461100C 4-imidazolin-2-one compounds
12/01/2009CA2432121C Nitric oxide synthase inhibitor phosphate salt
12/01/2009CA2418348C Oil/fat composition
12/01/2009CA2407210C Liposome drug delivery
11/2009
11/26/2009WO2009143367A2 Egf-a domain-mediated modulation of pcsk9
11/26/2009WO2009143363A2 Functional metabolomics coupled microfluidic chemotaxis device and identification of novel cell mediators
11/26/2009WO2009143065A2 Rice bran extracts and methods of use thereof
11/26/2009WO2009143049A1 Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
11/26/2009WO2009143010A1 Method for treating hyponatremia employing an sglt2 inhibitor and composition containing same
11/26/2009WO2009142321A1 Novel thiophenediamine derivative having urea structure
11/26/2009WO2009142242A1 Composition for preventing cardiovascular event in high-risk patient
11/26/2009WO2009141533A2 Pyrrole derivatives, preparation of same and therapeutic application thereof
11/26/2009WO2009141532A2 Pyrrole derivatives, preparation of same and therapeutic application thereof
11/26/2009WO2009141238A1 Gpr119 receptor agonists
11/26/2009WO2009140972A2 Modulation of the vps10p-domain receptors for the treatment of cardiovascular disease
11/26/2009WO2009140814A1 A method for preparing extractive containing sequoyitol from nephrolepis family and application
11/26/2009WO2009043458A3 Use of oxytocin to treat many diseases
11/26/2009WO2009043457A3 Use of human hemokinin-1 and optionally oxytocin to treat diseases involving excessive angiogenesis
11/26/2009WO2009040024A3 Use of bim-23127 and optionally urodilatin as therapeutic agents eg for the treatment of m. tuberculosis infections
11/26/2009WO2009039981A3 Use of (arg 8) vasopressin to treat eg s. pneumoniae infection
11/26/2009WO2009039980A3 Use of bfgf 1-24 and optionally (arg 8) vasopressin to treat eg s. pneumoniae infection
11/26/2009WO2009033820A3 Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis
11/26/2009WO2009033783A3 Use of carbetocin to treat of eg aids or idiopathic pulmonary fibrosis
11/26/2009WO2009033782A3 Use of a teprotide and optionally carbetocin to treat eg aids or idiopathic pulmonay fibrosis
11/26/2009US20090292016 Stable Pharmaceutical Compositions Containing Pravastatin
11/26/2009US20090292011 Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
11/26/2009US20090292005 L- alpha -dioleoyl phosphatidyl{14-N-(1-deoxylactito-1-yl)amino-3,6,9,12-tetraoxa}tetra decanol; 2-O-{2-N-(1-deoxylactito-1-yl)aminoethyl} carbamoyl-1,3-O-dioleoyl glycerol; galactose, a suitable spacer and a certain lipid, a drug carrier; efficiently transferred into the liver
11/26/2009US20090291982 New Substituted Oxindole Derivative 352
11/26/2009US20090291978 Enzyme Inhibitors
11/26/2009US20090291963 Substituted indoles
11/26/2009US20090291959 Caspase inhibitors based of pyridazinone scaffold
11/26/2009US20090291957 Heterocyclic derivatives and their use as therapeutic agents
11/26/2009US20090291955 Azacyclohexane Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase
11/26/2009US20090291953 Pharmaceutical salts of reboxetine
11/26/2009US20090291947 Proline analogs as ligands for cannabinoid receptors
11/26/2009US20090291946 Lactam compounds and their use as pharmaceuticals
11/26/2009US20090291917 Boron-Containing Small Molecules as Anti-Inflammatory Agents
11/26/2009US20090291915 Silicon Compounds and Their Use
11/26/2009US20090291897 Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
11/26/2009US20090291153 Health food, Method for producing the same and dried Product and Extract
11/26/2009US20090291100 Therapeutic agent for polycystic ovary syndrome (pcos)
11/26/2009US20090291050 Particulate materials
11/26/2009CA2761973A1 Rice bran extracts and methods of use thereof
11/26/2009CA2724983A1 Composition for preventing cardiovascular event in high-risk patient
11/26/2009CA2724426A1 Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
11/26/2009CA2724357A1 Novel thiophenediamine derivative having urea structure
11/26/2009CA2724011A1 Gpr119 receptor agonists
11/25/2009EP2123751A1 Novel peptide
11/25/2009EP2123677A1 Anti-brak (cxcl14) human monoclonal antibody and use thereof
11/25/2009EP2123672A1 Modulation of IL-2- and IL-15- mediated T cell responses
11/25/2009EP2123669A1 Copolymers for suppression of autoimmune diseases, and methods of use
11/25/2009EP2123652A1 Heterocyclic compound
11/25/2009EP2123649A1 3-pyrrolo-cyclohexylene-2-dihydro-indolinone derivatives and uses thereof
11/25/2009EP2123644A1 Benzoxazepine derivatives and use thereof
11/25/2009EP2123643A1 Novel prophylactic and/or therapeutic agent for diabetic neuropathy
11/25/2009EP2123636A1 Method for producing aminoacetylpyrrolidinecarbonitrile derivative
11/25/2009EP2123303A1 Ameliorating agent for insulin resistance
11/25/2009EP2123297A1 Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient
11/25/2009EP2123293A2 Peptide YY and petide YY agonists for treatment of metabolic disorders
11/25/2009EP2123270A1 Iron metabolism-improving agent
11/25/2009EP2123257A2 Stable high Vitamin C content polyol-in-oil emulsified system and its preparation
11/25/2009EP2123171A1 Feed mixture
11/25/2009EP2121751A2 Monoclonal antibodies against angptl3
11/25/2009EP2121659A1 Modulators of cb1 receptors
11/25/2009EP2121627A1 Benzimidazole derivatives
11/25/2009EP2121621A1 Lxr and fxr modulators
11/25/2009EP2121617A1 Cb1 receptor modulators
11/25/2009EP2121600A2 Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions
11/25/2009EP2121599A2 Nitroxides for use in treating or preventing hypercholesterolemia
11/25/2009EP2121596A1 Atorvastatin strontium salt and pharmaceutical composition comprising same
11/25/2009EP2121591A2 Ppar active compounds
11/25/2009EP2120995A2 The secreted protein ccdc80 regulates adipocyte differentiation
11/25/2009EP2120994A2 Methods and compositions for treating hypoglycemic disorders
11/25/2009EP2120980A1 An anti-diabetic extract of rooibos
11/25/2009EP2120979A1 Process for harvesting plants of the apocynaceae family
11/25/2009EP2120954A1 Adenosine derivatives as partial and full agonists of a1 adenosine receptors
11/25/2009EP2120930A1 Use of chromium histidinate for treatment of cardiometabolic disorders
11/25/2009EP2120927A1 Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
11/25/2009EP2120923A1 Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
11/25/2009EP2120911A1 Amide and urea derivatives for the treatment of metabolic diseases
11/25/2009EP2120909A2 Treatments of therapy-resistant diseases comprising drug combinations
11/25/2009EP2120905A1 Methods, compounds, and compositions for treating metabolic disorders and diabetes
11/25/2009EP2120882A2 Pharmaceutical composition containing a cholesterol absorption inhibitor
11/25/2009EP2120580A2 Compositions and methods for the treatment of metabolic disorders
11/25/2009EP2120569A2 Spirochromanon derivatives
11/25/2009EP2120567A1 Prodrugs of substituted 1,3-dioxanes and their uses
1 ... 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 ... 1298